Side-by-side · Research reference
DSIPvsP21
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticAUTO-DRAFTED8/36 cited
BAnimal-MechanisticHUMAN-REVIEWED8/36 cited
DSIP
Sleep modulator · Anti-stress
SQ · Pre-sleep · Daily during cycle
P21
CNTF-Derived Neuropeptide · Animal Model Evidence
Animal onlyEvidence level
SQ · Site unspecified · Frequency unknown
01Mechanism of Action
Parameter
DSIP
P21
Primary target
Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986
CNTF receptor alpha (CNTFRα) / LIF receptor (LIFR) / gp130 complex on neural stem cells
Pathway
Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986
CNTF mimetic → CNTFRα/LIFR/gp130 heterotrimer → JAK/STAT3 signaling → neurogenesis, stem cell proliferation, neuroprotection
Downstream effect
Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986
Increased neural stem cell self-renewal, globose basal cell activation (Mash1+ cells), olfactory sensory neuron regeneration, hippocampal neurogenesis, neuroprotection in developmental disorders
Feedback intact?
—
—
Origin
Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986
Small-molecule peptide mimetic derived from full-length ciliary neurotrophic factor (CNTF), designed to retain receptor activation with improved pharmacokineticsMottolese 2024
Antibody development
—
—
02Dosage Protocols
Parameter
DSIP
P21
Frequency
Once daily, pre-sleep
—
Lower / starter dose
50 mcg pre-sleep
—
Evidence basis
Human-mechanistic + early clinicalSchneider 1986
Animal models only
CDKL5 KO mice, methimazole-induced olfactory injury, CNTF-/- knockout models.Mottolese 2024Cox 2026Jia 2020
Duration
8–12 weeks per cycle
Not specified
Reconstitution
Bacteriostatic water
—
Timing
30–60 min pre-sleep
—
Half-life
Short plasma; CNS effects last hours
—
Human dosing
—
No established protocol
No clinical trial data available.
Animal models (mice)
—
Dose and route not specified in abstractsMottolese 2024Jia 2020
In vitro and in vivo studies demonstrate efficacy; precise dosing protocols not disclosed.
Route
—
Presumed subcutaneous or intraperitoneal (animal studies)
04Side Effects & Safety
Parameter
DSIP
P21
Injection site reaction
Mild irritation
—
Drowsiness
Expected effect (intentional)
—
Vivid dreams
Anecdotally reported
—
Long-term safety
Limited modern RCT data
—
Pregnancy / OB
Avoid
—
Human safety data
—
None available
No clinical trials in humans.
Animal tolerability
—
Well-tolerated in mouse models; no toxicity reported in available abstracts
Theoretical risks
—
Uncontrolled stem cell proliferation, immune response to peptide, unknown long-term CNS effects
Absolute Contraindications
DSIP
- ·Pregnancy / breastfeeding
- ·Concurrent CNS-depressant therapy without supervision
P21
- ·Use in humans not validated
Relative Contraindications
DSIP
- ·Severe sleep apnoea (untreated)
- ·Concurrent benzodiazepine / opioid use
P21
- ·Active malignancy (theoretical — neurotrophic signaling may affect tumour growth)
- ·Pregnancy or lactation (no safety data)
05Administration Protocol
Parameter
DSIP
P21
1. Reconstitution
Add 1–2 mL bacteriostatic water to vial.
Not established. No FDA approval, no clinical trial data.
2. Injection site
SQ — abdomen. Rotate sites.
In vivo studies used systemic administration (route not specified in abstracts) in mouse models of neurodegeneration, olfactory injury, and CDKL5 deficiency disorder. In vitro studies used primary cell cultures.
3. Timing
30–60 min pre-sleep.
—
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
—
5. Needle
29–31G insulin syringe.
—